PTC Therapeutics Completes Acquisition of Sangamo's ST-920 Gene Therapy
PTC Therapeutics completed its acquisition of ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.